This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)

This study has been completed.
Information provided by:
Cordis Corporation Identifier:
First received: October 4, 2005
Last updated: April 3, 2007
Last verified: April 2007
The purpose of this PMS registry, named e-CYPHER Stent Registry, is to collect post marketing surveillance data on the CYPHERTM Sirolimus-eluting Coronary Stent following marketing approval, when used in normal clinical practice within the labeled indications.

Condition Intervention Phase
Coronary Artery Disease Device: CYPHERTM Sirolimus-Eluting Coronary Stent Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)

Resource links provided by NLM:

Further study details as provided by Cordis Corporation:

Primary Outcome Measures:
  • MACE at 30 days, 6 months and 1 year.

Secondary Outcome Measures:
  • There is no pre-specified secondary outcome.

Estimated Enrollment: 2070
Study Start Date: August 2003
Study Completion Date: December 2004

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cypher stent

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00245401

Sponsors and Collaborators
Cordis Corporation
Principal Investigator: Emerson Perin, MD Texas Heart Institute
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00245401     History of Changes
Other Study ID Numbers: P03-6321
Study First Received: October 4, 2005
Last Updated: April 3, 2007

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on September 19, 2017